pembrolizumab intravesical (LP-50) / Lipella Pharma - LARVOL DELTA

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology (GlobeNewswire) - "Lipella Pharmaceuticals...announced the issuance of U.S. Patent No. 12,326,492, titled 'Systems and Methods of Detecting Interstitial Cystitis.' The patent was issued by the United States Patent and Trademark Office on June 10, 2025, and provides protection through at least 2045, subject to potential extensions. The patent covers a method, using magnetic resonance imaging (MRI), to detect lesions (or permeability defects) in body cavities. 'This method can potentially provide enhanced outcome assessments to our development programs; especially mucosal disorders, including our existing programs...LP-50 for bladder cancer'."

Patent • Bladder Cancer

Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) - "Lipella Pharmaceuticals Inc...announces an abstract publication at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, taking place from May 31 - June 4 in Chicago, IL, and online. Lipella’s abstract...highlights new preclinical results from LP-50 (intravesical pembrolizumab) in induced murine non-muscle invasive bladder cancer (NMIBC)....'Our preclinical results have demonstrated promising results, demonstrating LP-50’s potential for increasing efficacy while minimizing systemic toxicity.'"

Preclinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024 (GlobeNewswire) - "Lipella Pharmaceuticals Inc...today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois. Lipella’s abstract, 'Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published..."

Preclinical